%0 Journal Article
%A Kind, Felix
%A Eder, Ann-Christin
%A Jilg, Cordula A
%A Hartrampf, Philipp E
%A Meyer, Philipp T
%A Ruf, Juri
%A Michalski, Kerstin
%T Prognostic Value of Tumor Volume Assessment on PSMA PET After 177Lu-PSMA Radioligand Therapy Evaluated by PSMA PET/CT Consensus Statement and RECIP 1.0.
%J Journal of nuclear medicine
%V 64
%N 4
%@ 0097-9058
%C New York, NY
%I Soc.
%M DKFZ-2023-00701
%P 605 - 610
%D 2023
%X Quantitative evaluation of prostate-specific membrane antigen (PSMA)-targeting PET/CT remains challenging but is urgently needed for the use of standardized PET-based response criteria, such as the PSMA PET/CT consensus statement or Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0). A recent study evaluated the prognostic value of whole-body tumor volume using a semiautomatic method relying on a 50
%K Male
%K Humans
%K Prognosis
%K Positron Emission Tomography Computed Tomography: methods
%K Retrospective Studies
%K Treatment Outcome
%K Prostate-Specific Antigen
%K Tumor Burden
%K Prostatic Neoplasms, Castration-Resistant: diagnostic imaging
%K Prostatic Neoplasms, Castration-Resistant: radiotherapy
%K Dipeptides: adverse effects
%K Heterocyclic Compounds, 1-Ring: adverse effects
%K Lutetium
%K PSMA PET/CT (Other)
%K PSMATV50 (Other)
%K RECIP 1.0 (Other)
%K radioligand therapy (Other)
%K response assessment (Other)
%K gallium 68 PSMA-11 (NLM Chemicals)
%K Prostate-Specific Antigen (NLM Chemicals)
%K Dipeptides (NLM Chemicals)
%K Heterocyclic Compounds, 1-Ring (NLM Chemicals)
%K Lutetium (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:36302658
%R 10.2967/jnumed.122.264489
%U https://inrepo02.dkfz.de/record/275254